supply chain and make sure that we have a more resilient access to raw materials or the active pharmaceutical ingredients, if we could provide incentives for our manufacturers to be developing these generic drugs, and we also have to look at the relationships between the gpos, the group purchasing organizations, and the pharmaceutical benefit managers between the manufacturers and who they re selling to. it s an important story. it s very important that you got that out and the idea that it s even more than the new york times just reported is stunning. doctor, thank you so much for being with us. we really appreciate it. well, the next five years could get very very hot. the latest troubling analysis warning of the direct consequences of climate change next. but first, amazing new evidence of an exo planet in our galaxy, similar in size to earth. you probably don t want to live there because astronomers say the rocky and rugged planet,
For two decades, patients and physicians eagerly awaited a lower-cost version of the world's bestselling drug, Humira, while its maker, AbbVie, fought off potential competitors by building a wall of more than 250 patents around it.
Sen. Bernie Sanders, Vermont independent, likes to fancy himself one of the only independent voices and minds in Congress. Unfortunately, however, when it comes to Big Pharma, he's just another mud-covered politician.